1Ugurel S, Hildenbrand R, Dippel E, et al. Dose-dependent se-vere cutaneous reactions to imatinib[J]. Br J Cancer, 2003, 88 (8): 1157-1159.
2Drummond A, Micallef-Eynaud P, Douglas WS, etal. A spec- trum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec)[J], Br J Haematol, 2003, 120(5): 911-913.
3Hsieh HJ, Chan AL, Lin SJ. Stevens-Johnson syndrome induced by combination of imatinib and allopurinol [J]. Chemotherapy, 2009, 55(4): 197-199.
7Vano-Galvan S, Fernandez-Guarino M, Henriquez-Santana A, et al. Imatinib-induced erythroderma mediated by an unusual non- dose-dependent mechanism[J]. Eur J Dermatol, 2007, 17(6): 538-539.
8Hwang JE, Yoon JY, Bae WK, et al. Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor[J]. BMC Cancer, 2010, 10: 438.
9Schamun A, Bullorsky E, Stemmelin G, et al. Treatment with cyclospofin A cream for the cutaneous reactions associated with imatinib therapy[J]. Blood, 2005, 105(7): 2996-2997.
二级参考文献23
1Gambillara E, Laffitte E, Widmer N, et al. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia[ J ]. Dermatology, 2005, 211 (4): 363-365.
2Brouard M, Saurat JH. Cutaneous reactions to STI571 [J]. N Engl J Med, 2001, 345(8): 618-619.
3Arora B, Knmar L, Sharma A, et al. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate[J]. Ann Oncol, 2004, 15(2): 358-359.
4Huang X, Patel S, Ahmed N, et al. Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors [J]. Drug Des Devel Ther, 2008, 2: 215-219.
5Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia[J]. N Engl J Med, 2001, 344( 14): 1031-1037.
6Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome [J]. N Engl J Med, 2001, 344( 14): 1038-1042.
7Ugurel S, Hildenbrand R, Dippel E, et al. Dose-dependent severe cutaneous reactions to imatinib [J]. Br J Cancer, 2003, 88(8): 1157-1159.
8Kawakami T, Kawanabe T, Soma Y. Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia[J]. Acta Derm Venereol, 2009, 89(3): 325-326.
9Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologis,2004,9(3):271-281.
10Ferraresi V, Catricaltt C, Ciccarese M. Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate. Anticancer Res,2006,26(6C) :4771-4774.
